Get the Stockscreener App
99.62
4.64%
4.42
Glaukos Corporation stock is traded at $99.62, with a volume of 1.29M.
It is up +4.64% in the last 24 hours and up +31.29% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$95.20
Open:
$94.94
24h Volume:
1.29M
Relative Volume:
1.19
Market Cap:
$5.72B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-33.66
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
+10.65%
1M Performance:
+31.29%
6M Performance:
+5.06%
1Y Performance:
-29.26%
1-Day Range:
$93.78
$99.73
1-Week Range:
$87.32
$99.73
52-Week Range:
$73.16
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
99.62 | 5.47B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Glaukos President & COO Joseph Gilliam Sells 39% Of Holding - simplywall.st
Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growth - MSN
Is Glaukos Corporation stock a safe buy before earningsTrade Risk Assessment & Low Drawdown Investment Ideas - newser.com
Investors Appear Satisfied With Glaukos Corporation's (NYSE:GKOS) Prospects As Shares Rocket 25% - simplywall.st
Will Glaukos Corporation stock benefit from infrastructure spendingWeekly Trading Summary & Daily Profit Focused Stock Screening - newser.com
Why analysts maintain buy rating on Glaukos Corporation stockJuly 2025 Retail & Verified Momentum Watchlists - newser.com
Glaukos gains as Goldman Sachs initiates at Buy on valuation - MSN
Glaukos Insider Sold Shares Worth $1,740,600, According to a Recent SEC Filing - MarketScreener
Gilliam, Glaukos Corp president, sells $1.74m in GKOS stock By Investing.com - Investing.com Nigeria
Gilliam, Glaukos Corp president, sells $1.74m in GKOS stock - Investing.com India
Why Glaukos Corporation stock stays undervaluedStop Loss & Capital Protection Trade Alerts - newser.com
How Glaukos Corporation stock moves in volatile trading sessions2025 Growth vs Value & Daily Volume Surge Trade Alerts - newser.com
How Glaukos Corporation stock performs in easing cycles2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com
Will Glaukos Corporation stock keep raising dividendsBuy Signal & Consistent Return Investment Signals - newser.com
Is Glaukos Corporation stock undervalued vs historical averagesMarket Movement Recap & AI Forecasted Entry and Exit Points - newser.com
Risk vs reward if holding onto Glaukos CorporationQuarterly Performance Summary & Scalable Portfolio Growth Ideas - newser.com
Backtesting results for Glaukos Corporation trading strategiesQuarterly Investment Review & Capital Efficient Trade Techniques - newser.com
Is Glaukos Corporation stock overvalued by current metricsJuly 2025 Action & Community Consensus Picks - newser.com
Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa - MSN
Key metrics from Glaukos Corporation’s quarterly dataWeekly Risk Summary & AI Optimized Trading Strategy Guides - newser.com
Will Glaukos Corporation continue its uptrendJuly 2025 EndofMonth & Risk Controlled Daily Trade Plans - newser.com
Why Glaukos Corporation stock appears on watchlistsJuly 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
How higher bond yields impact Glaukos Corporation stockPortfolio Value Report & Real-Time Volume Analysis Alerts - newser.com
Combining machine learning predictions for Glaukos CorporationPortfolio Profit Report & Breakout Confirmation Alerts - newser.com
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):